Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease

Kadoaki Ohashi, Yosef E. Maruvka, Franziska Michor, William Pao

Research output: Contribution to journalReview article

327 Citations (Scopus)

Abstract

Purpose EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here, we present an update on new controversies and conclusions regarding the disease. Methods This article reviews the clinical implications of EGFR mutations in lung cancer with a focus on epidermal growth factor receptor tyrosine kinase inhibitor resistance. Results The discovery of EGFR mutations has altered the ways in which we consider and treat non-small-cell lung cancer (NSCLC). Patients whose metastatic tumors harbor EGFR mutations are expected to live longer than 2 years, more than double the previous survival rates for lung cancer. Conclusion The information presented in this review can guide practitioners and help them inform their patients about EGFR mutations and their impact on the treatment of NSCLC. Efforts should now concentrate on making EGFR-mutant lung cancer a chronic rather than fatal disease.

Original languageEnglish
Pages (from-to)1070-1080
Number of pages11
JournalJournal of Clinical Oncology
Volume31
Issue number8
DOIs
Publication statusPublished - Mar 10 2013

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease'. Together they form a unique fingerprint.

  • Cite this